Co-administration with A1M does not influence apoptotic response of 177Lu-octreotate in GOT1 neuroendocrine tumors

[1]  Eva Forssell-Aronsson,et al.  Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model , 2022, Cancers.

[2]  D. Carpizo,et al.  Genetic Drivers of Ileal Neuroendocrine Tumors , 2021, Cancers.

[3]  S. Strand,et al.  Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy , 2021, Antioxidants.

[4]  S. Strand,et al.  177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging , 2021, Biomolecules.

[5]  Anushya Muruganujan,et al.  The Gene Ontology resource: enriching a GOld mine , 2020, Nucleic Acids Res..

[6]  G. Ichim,et al.  Apoptosis – Fueling the oncogenic fire , 2020, The FEBS journal.

[7]  S. Yendamuri,et al.  Exploring the role of survivin in neuroendocrine neoplasms , 2020, Oncotarget.

[8]  Yanfang Fu,et al.  Radiation induces apoptosis primarily through the intrinsic pathway in mammalian cells. , 2019, Cellular signalling.

[9]  Eva Forssell-Aronsson,et al.  Recombinant α1-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors , 2019, The Journal of Nuclear Medicine.

[10]  Eva Forssell-Aronsson,et al.  Protection of Kidney Function with Human Antioxidation Protein α1-Microglobulin in a Mouse 177Lu-DOTATATE Radiation Therapy Model , 2019, Antioxidants & redox signaling.

[11]  Eva Forssell-Aronsson,et al.  Multiparametric MR for non‐invasive evaluation of tumour tissue histological characteristics after radionuclide therapy , 2019, NMR in biomedicine.

[12]  Toshima Z. Parris,et al.  Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu[Lu]-octreotate therapy. , 2018, Nuclear medicine and biology.

[13]  Thawfeek M. Varusai,et al.  The Reactome Pathway Knowledgebase , 2017, Nucleic Acids Res..

[14]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[15]  Toshima Z. Parris,et al.  Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1 , 2017, EJNMMI Research.

[16]  L. Dizdar,et al.  Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia , 2016, Oncotarget.

[17]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[18]  L. Dizdar,et al.  Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma , 2016, British Journal of Cancer.

[19]  S. Strand,et al.  Human Anti-Oxidation Protein A1M—A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy , 2015, International journal of molecular sciences.

[20]  M. Gram,et al.  A1M, an extravascular tissue cleaning and housekeeping protein. , 2014, Free radical biology & medicine.

[21]  E. Larsson,et al.  Antioxidants Accelerate Lung Cancer Progression in Mice , 2014, Science Translational Medicine.

[22]  D. Newmeyer,et al.  The rheostat in the membrane: BCL-2 family proteins and apoptosis , 2013, Cell Death and Differentiation.

[23]  S. Fulda.  Inhibitor of Apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. , 2012, Cancer Treatment Reviews.

[24]  Eva Forssell-Aronsson,et al.  Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies , 2012, Neuroendocrinology.

[25]  Stephen R. Thomas,et al.  MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature , 2009, Journal of Nuclear Medicine.

[26]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[27]  Eva Forssell-Aronsson,et al.  Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour , 2005, British Journal of Cancer.

[28]  Eva Forssell-Aronsson,et al.  GOT1 Xenografted to Nude Mice: A Unique Model for in Vivo Studies on SSTR‐Mediated Radiation Therapy of Carcinoid Tumors , 2004, Annals of the New York Academy of Sciences.

[29]  Eva Forssell-Aronsson,et al.  Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. , 2001, International journal of radiation oncology, biology, physics.

[30]  Eva Forssell-Aronsson,et al.  Animal Model A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake , 2001 .

[31]  Da‐Gong Wang.  Apoptosis in neuroendocrine tumours , 1999, Clinical endocrinology.

[32]  K Eckerman,et al.  ICRP Publication 107. Nuclear decay data for dosimetric calculations. , 2008, Annals of the ICRP.